DRL
Location
Vlaams Brabant
Founded
1980-09-05
Website
Risk Signals
105 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Furniture, Catalog and Mail-Order Houses), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about DRL
Live alerts from global media, monitored by Business Radar
(economictimes.com)
jardiance: Himachal Pradesh high court restrains DRL from selling BI's diabetic drug Jardiance -
The drugmaker said it is reviewing legal options including filing an appeal against the court order. Dr Reddy's has launched copies of Jardiance (empagliflozin), which has valid patent in India until 2025. BI has sought restraining order on manufacture and sale of the drug.
Read more
(economictimes.com)
DRL: Department of Pharmaceuticals rejects drug price review pleas of DRL, Abbott -
The DoP has rejected a review petition filed by leading drug makers, including Dr Reddy's Laboratories (DRL) and Abbott Healthcare.
Read more